BD (NYSE: BDX) has completed its first full quarter as “New BD,” a “more focused medtech company,” according to CEO Tom Polen, who cited Street-beating third-quarter results as “early benefits” of this change.
The Franklin Lakes, New Jersey–based medical technology company reported a net income of $377 million, or $1.37 per diluted share, for the three months ended June 30, 2026, compared with $574 million, or $2.00 per share, in the same period last year.
On a continuing-operations basis (excluding the Biosciences & Diagnostics business sold to Waters Corp. in a multibillion-dollar deal in February, diluted EPS was $1.64, up 4.5% from $1.57 a year earlier, on revenue growth of 5.4% to $5.0 billion.
Excluding one-time items, earnings per share were $3.23, 9¢ ahead of Zacks Consensus Estimate of $3.14 on revenue of $4.89 billion.
BD stock was up 3.84% at $177.06 per share today in early trading. The S&P 500 was up slightly.
“We delivered a strong third quarter, with revenue, adjusted operating margin and adjusted EPS all ahead of our expectations,” said Tom Polen, chairman, CEO and president of BD. “Our first full quarter as New BD demonstrates the early benefits of a more focused MedTech company, with strong momentum across our key growth platforms, continued innovation and further progress through BD Excellence. We remain focused on disciplined execution, advancing our key growth platforms, expanding margins and allocating capital strategically to drive sustainable growth and long-term shareholder value.”
BD updated its full year guidance, expecting an adjusted EPS of $12.62 to $12.72, tighter than previous guidance of $12.52 to $12.72.
